First, 20 patients with T2D (approximately 14.5%) could not tolerate or did not prefer weekly dulaglutide administrations (reasons included cost, gastrointestinal side effects, dissatisfaction with the drug), and 56 (approximately 40.6%) could successfully discontinue insulin and use either weekly dulaglutide or OHAs and demonstrated glycemic effectiveness after the switch. Here, INS is linked to type 2 diabetes mellitus.